BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37390258)

  • 1. Clinical predictors and outcomes of non-expandable lung following percutaneous catheter drainage in lung cancer patients with malignant pleural effusion.
    Kim CH; Park JE; Cha JG; Park J; Choi SH; Seo H; Yoo SS; Lee SY; Cha SI; Park JY; Lim JK; Lee J
    Medicine (Baltimore); 2023 Jun; 102(26):e34134. PubMed ID: 37390258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of lung entrapment in malignant pleural effusion.
    Trovisco R; Freitas C; Serino M; Ferreira P; Martins B; Coelho D; Melo N; Fernandes G; Magalhães A; Bastos HN
    Pulmonology; 2022 Sep; ():. PubMed ID: 36180353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter-observer variation in image interpretation and the prognostic importance of non-expansile lung in malignant pleural effusion.
    Martin GA; Kidd AC; Tsim S; Halford P; Bibby A; Maskell NA; Blyth KG
    Respirology; 2020 Mar; 25(3):298-304. PubMed ID: 31433545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-Reported Outcome Measures in Patients with and without Non-Expandable Lung Secondary to Malignant Pleural Effusion-A Single-Centre Observational Study.
    Petersen JK; Fjaellegaard K; Rasmussen DB; Alstrup G; Høegholm A; Sidhu JS; Bhatnagar R; Clementsen PF; Laursen CB; Bodtger U
    Diagnostics (Basel); 2024 Jun; 14(11):. PubMed ID: 38893702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.
    Ren S; Terman DS; Bohach G; Silvers A; Hansen C; Colt H; Sahn SA
    Chest; 2004 Nov; 126(5):1529-39. PubMed ID: 15539723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.
    Azzopardi M; Thomas R; Muruganandan S; Lam DC; Garske LA; Kwan BC; Rashid Ali MR; Nguyen PT; Yap E; Horwood FC; Ritchie AJ; Bint M; Tobin CL; Shrestha R; Piccolo F; De Chaneet CC; Creaney J; Newton RU; Hendrie D; Murray K; Read CA; Feller-Kopman D; Maskell NA; Lee YC
    BMJ Open; 2016 Jul; 6(7):e011480. PubMed ID: 27381209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion.
    Takeuchi E; Okano Y; Machida H; Atagi K; Kondou Y; Kadota N; Hatakeyama N; Naruse K; Shinohara T
    Cancer Immunol Immunother; 2022 Feb; 71(2):365-372. PubMed ID: 34170380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions.
    Kasapoglu US; Arınç S; Gungor S; Irmak I; Guney P; Aksoy F; Bandak D; Hazar A
    Clin Respir J; 2016 Nov; 10(6):791-799. PubMed ID: 25764010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients.
    Lee YS; Nam HS; Lim JH; Kim JS; Moon Y; Cho JH; Ryu JS; Kwak SM; Lee HL
    BMC Cancer; 2017 Aug; 17(1):557. PubMed ID: 28830378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.
    Noro R; Kobayashi K; Usuki J; Yomota M; Nishitsuji M; Shimokawa T; Ando M; Hino M; Hagiwara K; Miyanaga A; Seike M; Kubota K; Gemma A;
    Thorac Cancer; 2020 Jul; 11(7):1876-1884. PubMed ID: 32421226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-EDIT: A Randomized Feasibility Trial of Elastance-Directed Intrapleural Catheter or Talc Pleurodesis in Malignant Pleural Effusion.
    Martin GA; Tsim S; Kidd AC; Foster JE; McLoone P; Chalmers A; Blyth KG
    Chest; 2019 Dec; 156(6):1204-1213. PubMed ID: 31374208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Association Between Pleural Fluid Exposure and Survival in Pleural Mesothelioma.
    Asciak R; Kanellakis NI; Bibby A; Kidd A; Gerry S; Mercer R; Maskell N; Blyth KG; Fsadni P; Montefort S; Psallidas I; Rahman NM
    Chest; 2021 Nov; 160(5):1925-1933. PubMed ID: 34119515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative study of video-assisted thoracoscopic surgery vs thoracic tube drainage in synthetic therapy for malignant pleural effusion secondary to non-small cell lung cancer].
    Gu LJ; Wang WJ
    Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jul; 26(7):1023-6. PubMed ID: 16864104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations.
    Schwalk AJ; Ost DE; Saltijeral SN; De La Garza H; Casal RF; Jimenez CA; Eapen GA; Lewis J; Rinsurongkawong W; Rinsurongkawong V; Lee J; Elamin Y; Zhang J; Roth JA; Swisher S; Heymach JV; Grosu HB
    Chest; 2021 Mar; 159(3):1256-1264. PubMed ID: 33217413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status?
    Abrao FC; Peixoto RD; de Abreu IR; Janini MC; Viana GG; de Oliveira MC; Younes RN
    J Surg Oncol; 2016 Apr; 113(5):570-4. PubMed ID: 26751412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis].
    Chella A; Ribechini A; Dini P; Adamo C; Mussi A; Angeletti CA
    Minerva Chir; 1994 Nov; 49(11):1077-82. PubMed ID: 7708227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is Systemic Anticancer Therapy Associated With Higher Rates of Malignant Pleural Effusion Control in People With Pharmacologically Sensitive Tumors?: A Retrospective Analysis of Prospectively Collected Data.
    Holling N; Patole S; Medford ARL; Maskell NA; Bibby AC
    Chest; 2021 Nov; 160(5):1915-1924. PubMed ID: 34023321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma.
    Verma A; Chopra A; Lee YW; Bharwani LD; Asmat AB; Aneez DB; Akbar FA; Lim AY; Chotirmall SH; Abisheganaden J
    Curr Drug Discov Technol; 2016; 13(2):68-76. PubMed ID: 27216707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial.
    Muruganandan S; Azzopardi M; Fitzgerald DB; Shrestha R; Kwan BCH; Lam DCL; De Chaneet CC; Rashid Ali MRS; Yap E; Tobin CL; Garske LA; Nguyen PT; Stanley C; Popowicz ND; Kosky C; Thomas R; Read CA; Budgeon CA; Feller-Kopman D; Maskell NA; Murray K; Lee YCG
    Lancet Respir Med; 2018 Sep; 6(9):671-680. PubMed ID: 30037711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival in Patients With Malignant Pleural Effusions Who Developed Pleural Infection: A Retrospective Case Review From Six UK Centers.
    Bibby AC; Clive AO; Slade GC; Morley AJ; Fallon J; Psallidas I; Pepperell JCT; Slade MG; Stanton AE; Rahman NM; Maskell NA
    Chest; 2015 Jul; 148(1):235-241. PubMed ID: 25429399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.